Status:
TERMINATED
A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
Lead Sponsor:
Genaera Corporation
Conditions:
"Wet" Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of blindness among adults age 50 or older ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of "wet" age-related macular degeneration
Exclusion
- Prior treatment for "wet" age-related macular degeneration in the affected eye in the past 3 months
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00139282
Start Date
June 1 2005
Last Update
November 28 2007
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
2
Eldorado Retina Associates
Louisville, Colorado, United States, 80027
3
Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States, 33426
4
National Ophthalmic Research Institute
Fort Myers, Florida, United States, 33912